Akshanth R. Polepally

1.2k total citations
37 papers, 879 citations indexed

About

Akshanth R. Polepally is a scholar working on Hepatology, Infectious Diseases and Epidemiology. According to data from OpenAlex, Akshanth R. Polepally has authored 37 papers receiving a total of 879 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hepatology, 12 papers in Infectious Diseases and 7 papers in Epidemiology. Recurrent topics in Akshanth R. Polepally's work include Hepatitis C virus research (17 papers), HIV/AIDS drug development and treatment (12 papers) and Endometriosis Research and Treatment (6 papers). Akshanth R. Polepally is often cited by papers focused on Hepatitis C virus research (17 papers), HIV/AIDS drug development and treatment (12 papers) and Endometriosis Research and Treatment (6 papers). Akshanth R. Polepally collaborates with scholars based in United States, Germany and France. Akshanth R. Polepally's co-authors include Rajeev Menon, Amit Khatri, Sandeep Dutta, Walid M. Awni, Thomas Podsadecki, Prajakta Badri, Haoyu Wang, Jiuhong Zha, Nael M. Mostafa and Beibei Hu and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Akshanth R. Polepally

37 papers receiving 865 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Akshanth R. Polepally United States 16 412 281 202 171 103 37 879
J. Vergniol France 13 514 1.2× 642 2.3× 53 0.3× 321 1.9× 86 0.8× 32 1.2k
M.P. Manns Germany 17 632 1.5× 623 2.2× 107 0.5× 133 0.8× 38 0.4× 113 1.1k
Junchao Cai United States 22 215 0.5× 262 0.9× 77 0.4× 140 0.8× 6 0.1× 55 2.0k
W P Tong United States 19 193 0.5× 179 0.6× 114 0.6× 1.1k 6.7× 29 0.3× 31 1.8k
Petra Glander Germany 26 103 0.3× 501 1.8× 227 1.1× 192 1.1× 35 0.3× 81 2.0k
Anther Keung United States 14 44 0.1× 193 0.7× 310 1.5× 384 2.2× 130 1.3× 24 948
Soo Ryang Kim Japan 15 500 1.2× 472 1.7× 65 0.3× 166 1.0× 40 0.4× 87 880
Natavudh Townamchai Thailand 15 73 0.2× 146 0.5× 124 0.6× 141 0.8× 29 0.3× 72 1.1k
Amit Khatri United States 22 593 1.4× 455 1.6× 285 1.4× 96 0.6× 166 1.6× 47 1.3k
Carla Washington United States 13 89 0.2× 153 0.5× 215 1.1× 264 1.5× 44 0.4× 31 896

Countries citing papers authored by Akshanth R. Polepally

Since Specialization
Citations

This map shows the geographic impact of Akshanth R. Polepally's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Akshanth R. Polepally with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Akshanth R. Polepally more than expected).

Fields of papers citing papers by Akshanth R. Polepally

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Akshanth R. Polepally. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Akshanth R. Polepally. The network helps show where Akshanth R. Polepally may publish in the future.

Co-authorship network of co-authors of Akshanth R. Polepally

This figure shows the co-authorship network connecting the top 25 collaborators of Akshanth R. Polepally. A scholar is included among the top collaborators of Akshanth R. Polepally based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Akshanth R. Polepally. Akshanth R. Polepally is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Patel, Maulik, Jalaja Potluri, Thomas Marbury, et al.. (2025). Pharmacokinetics and Safety of Navitoclax in Hepatic Impairment. Clinical Pharmacokinetics. 64(4). 611–617. 1 indexed citations
2.
Pemmaraju, Naveen, Tim C. P. Somervaille, Francesca Palandri, et al.. (2024). Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response. PubMed. 2(1). 100056–100056. 1 indexed citations
3.
Hoffman, David, Nils Boehm, Bruno C. Medeiros, et al.. (2023). Pharmacokinetics and immunogenicity of eftozanermin alfa in subjects with previously-treated solid tumors or hematologic malignancies: results from a phase 1 first-in-human study. Cancer Chemotherapy and Pharmacology. 93(4). 329–339. 1 indexed citations
4.
D’Souza, Anita, Nina Shah, Cesar Rodriguez, et al.. (2022). A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma. Journal of Clinical Oncology. 40(31). 3576–3586. 84 indexed citations
5.
Rodriguez, Cesar, Katja Weisel, Rachid Baz, et al.. (2022). Dose Escalation and Expansion of Abbv-383 in Combination with Anti-Cancer Regimens in Relapsed or Refractory Multiple Myeloma. Blood. 140(Supplement 1). 7326–7327. 2 indexed citations
6.
Demetri, George D., Jason J. Luke, Antoine Hollebecque, et al.. (2021). First-in-Human Phase I Study of ABBV-085, an Antibody–Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors. Clinical Cancer Research. 27(13). 3556–3566. 41 indexed citations
7.
Kumar, Shaji, Anita D’Souza, Nina Shah, et al.. (2021). A Phase 1 First-in-Human Study of Tnb-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma. Blood. 138(Supplement 1). 900–900. 36 indexed citations
8.
Polepally, Akshanth R., et al.. (2020). Effect of Elagolix Exposure on Clinical Efficacy End Points in Phase III Trials in Women With Endometriosis‐Associated Pain: An Application of Markov Model. CPT Pharmacometrics & Systems Pharmacology. 9(8). 466–475. 3 indexed citations
9.
Richardson, Paul G., Akshanth R. Polepally, Monica Motwani, et al.. (2020). A Phase 1b, Open-Label Study of Eftozanermin Alfa in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma. Blood. 136(Supplement 1). 16–17. 3 indexed citations
10.
Shebley, Mohamad, Akshanth R. Polepally, Ahmed Nader, et al.. (2019). Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis. Clinical Pharmacokinetics. 59(3). 297–309. 45 indexed citations
11.
Nader, Ahmed, Akshanth R. Polepally, Mohan Liu, et al.. (2018). Population Pharmacokinetics of Elagolix in Healthy Women and Women with Endometriosis. Clinical Pharmacokinetics. 57(10). 1295–1306. 23 indexed citations
12.
Polepally, Akshanth R., Haoyu Wang, Patrick Marroum, et al.. (2017). Application of Exposure-Response Analyses to Establish the Pharmacodynamic Similarity of a Once-Daily Regimen to an Approved Twice-Daily Dosing Regimen for the Treatment of HCV Infection. The AAPS Journal. 19(5). 1523–1535. 1 indexed citations
13.
Menon, Rajeev, Akshanth R. Polepally, Amit Khatri, Walid M. Awni, & Sandeep Dutta. (2017). Clinical Pharmacokinetics of Paritaprevir. Clinical Pharmacokinetics. 56(10). 1125–1137. 21 indexed citations
14.
Polepally, Akshanth R., Sven Mensing, Amit Khatri, et al.. (2016). Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies. Clinical Pharmacokinetics. 55(9). 1091–1101. 3 indexed citations
15.
Polepally, Akshanth R., Jennifer R. King, Emily O. Dumas, et al.. (2016). Drug–Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers. Clinical Pharmacokinetics. 55(8). 1003–1014. 25 indexed citations
16.
Gopalakrishnan, Sathej, Akshanth R. Polepally, Sven Mensing, Amit Khatri, & Rajeev Menon. (2016). Population Pharmacokinetics of Paritaprevir, Ombitasvir, and Ritonavir in Japanese Patients with Hepatitis C Virus Genotype 1b Infection. Clinical Pharmacokinetics. 56(1). 1–10. 15 indexed citations
17.
Lalezari, Jacob, Peter Varunok, Kris V. Kowdley, et al.. (2015). Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. Journal of Hepatology. 63(2). 364–369. 88 indexed citations
18.
19.
Menon, Rajeev, Prajakta Badri, Tianli Wang, et al.. (2015). Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. Journal of Hepatology. 63(1). 20–29. 107 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J. Vergniol Breakdown of academic impact, for papers by M.P. Manns Breakdown of academic impact, for papers by Junchao Cai Breakdown of academic impact, for papers by W P Tong Breakdown of academic impact, for papers by Petra Glander Breakdown of academic impact, for papers by Anther Keung Breakdown of academic impact, for papers by Soo Ryang Kim Breakdown of academic impact, for papers by Natavudh Townamchai Breakdown of academic impact, for papers by Amit Khatri Breakdown of academic impact, for papers by Carla Washington
Rankless by CCL
2026